JP2013525443A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013525443A5 JP2013525443A5 JP2013508167A JP2013508167A JP2013525443A5 JP 2013525443 A5 JP2013525443 A5 JP 2013525443A5 JP 2013508167 A JP2013508167 A JP 2013508167A JP 2013508167 A JP2013508167 A JP 2013508167A JP 2013525443 A5 JP2013525443 A5 JP 2013525443A5
- Authority
- JP
- Japan
- Prior art keywords
- hydroxy
- dione
- diene
- bond
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 52
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 18
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical group OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 208000030533 eye disease Diseases 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 10
- 230000007812 deficiency Effects 0.000 claims description 10
- 239000012453 solvate Substances 0.000 claims description 9
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 8
- 201000004569 Blindness Diseases 0.000 claims description 8
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 8
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 230000004393 visual impairment Effects 0.000 claims description 8
- 208000014644 Brain disease Diseases 0.000 claims description 6
- 208000032274 Encephalopathy Diseases 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 6
- 230000000750 progressive effect Effects 0.000 claims description 6
- FGYKUFVNYVMTAM-UHFFFAOYSA-N (R)-2,5,8-trimethyl-2-(4,8,12-trimethyl-trideca-3t,7t,11-trienyl)-chroman-6-ol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-UHFFFAOYSA-N 0.000 claims description 5
- LNOVHERIIMJMDG-KTWAZNHYSA-N 2-[(6e,10e)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl]-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O LNOVHERIIMJMDG-KTWAZNHYSA-N 0.000 claims description 5
- FGYKUFVNYVMTAM-YMCDKREISA-N beta-Tocotrienol Natural products Oc1c(C)c2c(c(C)c1)O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CC2 FGYKUFVNYVMTAM-YMCDKREISA-N 0.000 claims description 5
- FGYKUFVNYVMTAM-MUUNZHRXSA-N epsilon-Tocopherol Natural products OC1=CC(C)=C2O[C@@](CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-MUUNZHRXSA-N 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 239000011723 β-tocotrienol Substances 0.000 claims description 5
- FGYKUFVNYVMTAM-WAZJVIJMSA-N β-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-WAZJVIJMSA-N 0.000 claims description 5
- 235000019151 β-tocotrienol Nutrition 0.000 claims description 5
- SFVAYPRWECRHTF-QRCIITMISA-N 2-[(6e,10e)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl]-6-methylcyclohexa-2,5-diene-1,4-dione Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(C)(O)CCC1=CC(=O)C=C(C)C1=O SFVAYPRWECRHTF-QRCIITMISA-N 0.000 claims description 4
- 102000014461 Ataxins Human genes 0.000 claims description 4
- 108010078286 Ataxins Proteins 0.000 claims description 4
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 4
- 201000002169 Mitochondrial myopathy Diseases 0.000 claims description 4
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims description 4
- 208000030768 Optic nerve injury Diseases 0.000 claims description 4
- 208000017442 Retinal disease Diseases 0.000 claims description 4
- 206010038923 Retinopathy Diseases 0.000 claims description 4
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 4
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims description 4
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 208000001799 Hereditary Optic Atrophies Diseases 0.000 claims description 3
- 208000022873 Ocular disease Diseases 0.000 claims description 3
- 206010068786 Overlap syndrome Diseases 0.000 claims description 3
- 208000027073 Stargardt disease Diseases 0.000 claims description 3
- 150000004677 hydrates Chemical class 0.000 claims description 3
- 208000027653 severe early-childhood-onset retinal dystrophy Diseases 0.000 claims description 3
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 2
- 208000002155 Cytochrome-c Oxidase Deficiency Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 102000015782 Electron Transport Complex III Human genes 0.000 claims description 2
- 108010024882 Electron Transport Complex III Proteins 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims description 2
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 claims description 2
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims description 2
- 208000026072 Motor neurone disease Diseases 0.000 claims description 2
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims description 2
- 208000021642 Muscular disease Diseases 0.000 claims description 2
- 201000009623 Myopathy Diseases 0.000 claims description 2
- 208000014060 Niemann-Pick disease Diseases 0.000 claims description 2
- 206010030113 Oedema Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000035965 Postoperative Complications Diseases 0.000 claims description 2
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 2
- 201000009028 early myoclonic encephalopathy Diseases 0.000 claims description 2
- 239000003889 eye drop Substances 0.000 claims description 2
- 230000000642 iatrogenic effect Effects 0.000 claims description 2
- 238000002647 laser therapy Methods 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 208000012268 mitochondrial disease Diseases 0.000 claims description 2
- 208000005264 motor neuron disease Diseases 0.000 claims description 2
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 108010007425 oligomycin sensitivity conferring protein Proteins 0.000 claims description 2
- 206010030875 ophthalmoplegia Diseases 0.000 claims description 2
- 208000001749 optic atrophy Diseases 0.000 claims description 2
- 238000002428 photodynamic therapy Methods 0.000 claims description 2
- 150000004053 quinones Chemical class 0.000 claims description 2
- 208000032253 retinal ischemia Diseases 0.000 claims description 2
- 238000011476 stem cell transplantation Methods 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- ODADKLYLWWCHNB-LDYBVBFYSA-N δ-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-LDYBVBFYSA-N 0.000 claims description 2
- 125000000687 hydroquinonyl group Chemical group C1(O)=C(C=C(O)C=C1)* 0.000 claims 7
- 239000002207 metabolite Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims 2
- 229930003802 tocotrienol Natural products 0.000 claims 2
- 239000011731 tocotrienol Substances 0.000 claims 2
- 235000019148 tocotrienols Nutrition 0.000 claims 2
- BAJMRJCHXAVVDA-UHFFFAOYSA-N 2-(3-hydroxy-3,7,11-trimethyldodec-6-enyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione Chemical compound CC(C)CCCC(C)=CCCC(C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O BAJMRJCHXAVVDA-UHFFFAOYSA-N 0.000 claims 1
- MGBINMNFHMKVGO-UHFFFAOYSA-N 2-(3-hydroxy-3,7,11-trimethyldodec-6-enyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione Chemical compound COC1=C(OC)C(=O)C(CCC(C)(O)CCC=C(C)CCCC(C)C)=C(C)C1=O MGBINMNFHMKVGO-UHFFFAOYSA-N 0.000 claims 1
- MDHGSGLUXLJWNW-UHFFFAOYSA-N 2-(3-hydroxy-3,7,11-trimethyldodeca-6,10-dienyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione Chemical compound CC(C)=CCCC(C)=CCCC(C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O MDHGSGLUXLJWNW-UHFFFAOYSA-N 0.000 claims 1
- HXHULRCWEGHYFQ-UHFFFAOYSA-N 2-(3-hydroxy-3,7,11-trimethyldodeca-6,10-dienyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione Chemical compound COC1=C(OC)C(=O)C(CCC(C)(O)CCC=C(C)CCC=C(C)C)=C(C)C1=O HXHULRCWEGHYFQ-UHFFFAOYSA-N 0.000 claims 1
- XBCVZPHYCOXGAQ-UHFFFAOYSA-N 2-(3-hydroxy-3,7-dimethyloct-6-enyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione Chemical compound CC(C)=CCCC(C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O XBCVZPHYCOXGAQ-UHFFFAOYSA-N 0.000 claims 1
- MYSOCZSFZLKWER-UHFFFAOYSA-N 2-(3-hydroxy-3,7-dimethyloct-6-enyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione Chemical compound COC1=C(OC)C(=O)C(CCC(C)(O)CCC=C(C)C)=C(C)C1=O MYSOCZSFZLKWER-UHFFFAOYSA-N 0.000 claims 1
- RIVQRFPJJUPASM-UHFFFAOYSA-N 5-(3-hydroxy-3,7,11-trimethyldodeca-6,10-dienyl)-2,3-dimethylcyclohexa-2,5-diene-1,4-dione Chemical compound CC(C)=CCCC(C)=CCCC(C)(O)CCC1=CC(=O)C(C)=C(C)C1=O RIVQRFPJJUPASM-UHFFFAOYSA-N 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims 1
- 208000028226 Krabbe disease Diseases 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 238000004140 cleaning Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 210000001328 optic nerve Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 16
- 238000009472 formulation Methods 0.000 description 14
- OTXNTMVVOOBZCV-UHFFFAOYSA-N 2R-gamma-tocotrienol Natural products OC1=C(C)C(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-UHFFFAOYSA-N 0.000 description 4
- RZFHLOLGZPDCHJ-DLQZEEBKSA-N alpha-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)(C)CCc2c1C RZFHLOLGZPDCHJ-DLQZEEBKSA-N 0.000 description 4
- OTXNTMVVOOBZCV-YMCDKREISA-N gamma-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CCc2c1 OTXNTMVVOOBZCV-YMCDKREISA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011722 γ-tocotrienol Substances 0.000 description 3
- OTXNTMVVOOBZCV-WAZJVIJMSA-N γ-tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-WAZJVIJMSA-N 0.000 description 3
- 235000019150 γ-tocotrienol Nutrition 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 2
- ODADKLYLWWCHNB-UHFFFAOYSA-N 2R-delta-tocotrienol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940064063 alpha tocotrienol Drugs 0.000 description 1
- BTNBMQIHCRIGOU-UHFFFAOYSA-N delta-tocotrienol Natural products CC(=CCCC(=CCCC(=CCCOC1(C)CCc2cc(O)cc(C)c2O1)C)C)C BTNBMQIHCRIGOU-UHFFFAOYSA-N 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 125000004151 quinonyl group Chemical group 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- RZFHLOLGZPDCHJ-XZXLULOTSA-N α-Tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C RZFHLOLGZPDCHJ-XZXLULOTSA-N 0.000 description 1
- 239000011730 α-tocotrienol Substances 0.000 description 1
- 235000019145 α-tocotrienol Nutrition 0.000 description 1
- 239000011729 δ-tocotrienol Substances 0.000 description 1
- 235000019144 δ-tocotrienol Nutrition 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32854610P | 2010-04-27 | 2010-04-27 | |
| US61/328,546 | 2010-04-27 | ||
| US39369310P | 2010-10-15 | 2010-10-15 | |
| US61/393,693 | 2010-10-15 | ||
| PCT/US2011/033983 WO2011137126A1 (en) | 2010-04-27 | 2011-04-26 | Formulations of quinones for the treatment of ophthalmic diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016046881A Division JP6266674B2 (ja) | 2010-04-27 | 2016-03-10 | 眼疾患の処置のためのキノンの製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013525443A JP2013525443A (ja) | 2013-06-20 |
| JP2013525443A5 true JP2013525443A5 (cg-RX-API-DMAC7.html) | 2014-06-19 |
| JP5902673B2 JP5902673B2 (ja) | 2016-04-13 |
Family
ID=44861894
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013508167A Expired - Fee Related JP5902673B2 (ja) | 2010-04-27 | 2011-04-26 | 眼疾患の処置のためのキノンの製剤 |
| JP2016046881A Expired - Fee Related JP6266674B2 (ja) | 2010-04-27 | 2016-03-10 | 眼疾患の処置のためのキノンの製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016046881A Expired - Fee Related JP6266674B2 (ja) | 2010-04-27 | 2016-03-10 | 眼疾患の処置のためのキノンの製剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20130109759A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2563352A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5902673B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN105147651A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011245384C1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112012027543A8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2797581A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201201465A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX337594B (cg-RX-API-DMAC7.html) |
| MY (1) | MY183449A (cg-RX-API-DMAC7.html) |
| SG (2) | SG10201801321XA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011137126A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201208535B (cg-RX-API-DMAC7.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005033093A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | 7,8-bicycloalkyl-chroman derivatives |
| DK2471530T3 (en) | 2005-06-01 | 2017-04-10 | Edison Pharmaceuticals Inc | REDOXACTIVE THERAPEUTIC AGENTS FOR THE TREATMENT OF MITOCONDARY DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS |
| EP1986636B1 (en) | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
| HUE028502T2 (en) | 2007-11-06 | 2016-12-28 | Edison Pharmaceuticals Inc | 4- (P-Quinonyl) -2-hydroxybutanamide derivatives for the treatment of mitochondrial diseases |
| EP2237664A4 (en) * | 2008-01-08 | 2013-05-22 | Edison Pharmaceuticals Inc | (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES |
| US8716527B2 (en) | 2008-03-05 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases |
| US8716486B2 (en) * | 2008-06-25 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| LT3827815T (lt) | 2008-09-10 | 2023-10-10 | Ptc Therapeutics, Inc. | Psichologinių raidos sutrikimų gydymas oksidacijos redukcijos atžvilgiu aktyviais vaistais |
| US10039722B2 (en) | 2008-10-14 | 2018-08-07 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| ES2553557T3 (es) | 2008-10-28 | 2015-12-10 | Edison Pharmaceuticals, Inc. | Proceso para la producción de alfa-tocotrienol y derivados |
| HUE037574T2 (hu) | 2009-04-28 | 2018-09-28 | Bioelectron Tech Corp | Leber-féle örökletes optikus neuropátia és domináns optikus atrofia kezelése tokotrienol kinonokkal |
| US20110207828A1 (en) * | 2009-08-26 | 2011-08-25 | Miller Guy M | Methods for the prevention and treatment of cerebral ischemia |
| JP2013523816A (ja) * | 2010-04-06 | 2013-06-17 | エジソン ファーマシューティカルズ， インコーポレイテッド | 毛細血管拡張性運動失調症の治療 |
| MY183449A (en) * | 2010-04-27 | 2021-02-18 | Bioelectron Tech Corp | Formulations of quinones for the treatment of ophthalmic diseases |
| WO2012174286A1 (en) | 2011-06-14 | 2012-12-20 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
| WO2013013078A1 (en) | 2011-07-19 | 2013-01-24 | Edison Pharmeceuticals, Inc. | Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols |
| US9629815B2 (en) | 2012-09-07 | 2017-04-25 | Bioelectron Technology Corporation | Benzoquinone derivatives for treating oxidative stress disorders |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| CA2906145A1 (en) | 2013-03-15 | 2014-09-18 | Edison Pharmaceuticals, Inc. | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| NZ733528A (en) | 2014-12-16 | 2021-07-30 | Ptc Therapeutics Inc | Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide |
| JP7117241B2 (ja) | 2015-12-16 | 2022-08-12 | ピーティーシー セラピューティクス， インコーポレイテッド | 混合されたトコール組成物からアルファ－トコトリエノールを富化するための改良された方法 |
| CA3008849A1 (en) | 2015-12-17 | 2017-06-22 | Bioelectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| US11260048B2 (en) | 2017-10-03 | 2022-03-01 | The Schepens Eye Research Institute, Inc. | Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same |
| HUE066196T2 (hu) | 2018-10-17 | 2024-07-28 | Ptc Therapeutics Inc | 2,3,5-trimetil-6-nonilciklohexa-2,5-dién-1,4-dion alfa-szinukleinopátiák, tauopátiák és egyéb rendellenességek szuppresszálására és kezelésére |
| JP7705106B2 (ja) * | 2019-05-28 | 2025-07-09 | ナノ－ネオ リミテッド | 網膜症を治療するための組成物及び方法 |
| CA3225266A1 (en) | 2021-07-08 | 2023-01-12 | Swathi PINNAMANENI | Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione |
| WO2025231245A1 (en) * | 2024-05-02 | 2025-11-06 | Stealth Biotherapeutics Inc. | Use of substituted 1,4 benzoquinones to treat alpha-synucleinopathies |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2471530T3 (en) * | 2005-06-01 | 2017-04-10 | Edison Pharmaceuticals Inc | REDOXACTIVE THERAPEUTIC AGENTS FOR THE TREATMENT OF MITOCONDARY DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS |
| EP1924292A2 (en) * | 2005-09-16 | 2008-05-28 | Allergan, Inc. | Compositions and methods for the intraocular transport of therapeutic agents |
| EP1986636B1 (en) * | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
| LT3827815T (lt) * | 2008-09-10 | 2023-10-10 | Ptc Therapeutics, Inc. | Psichologinių raidos sutrikimų gydymas oksidacijos redukcijos atžvilgiu aktyviais vaistais |
| US20110207828A1 (en) * | 2009-08-26 | 2011-08-25 | Miller Guy M | Methods for the prevention and treatment of cerebral ischemia |
| JP2013523816A (ja) * | 2010-04-06 | 2013-06-17 | エジソン ファーマシューティカルズ， インコーポレイテッド | 毛細血管拡張性運動失調症の治療 |
| MY183449A (en) * | 2010-04-27 | 2021-02-18 | Bioelectron Tech Corp | Formulations of quinones for the treatment of ophthalmic diseases |
-
2011
- 2011-04-26 MY MYPI2012004738A patent/MY183449A/en unknown
- 2011-04-26 EP EP11775506.6A patent/EP2563352A4/en not_active Withdrawn
- 2011-04-26 JP JP2013508167A patent/JP5902673B2/ja not_active Expired - Fee Related
- 2011-04-26 CA CA2797581A patent/CA2797581A1/en not_active Abandoned
- 2011-04-26 SG SG10201801321XA patent/SG10201801321XA/en unknown
- 2011-04-26 WO PCT/US2011/033983 patent/WO2011137126A1/en not_active Ceased
- 2011-04-26 BR BR112012027543A patent/BR112012027543A8/pt not_active IP Right Cessation
- 2011-04-26 AU AU2011245384A patent/AU2011245384C1/en not_active Ceased
- 2011-04-26 SG SG2012079323A patent/SG185046A1/en unknown
- 2011-04-26 EA EA201201465A patent/EA201201465A1/ru unknown
- 2011-04-26 CN CN201510490746.XA patent/CN105147651A/zh active Pending
- 2011-04-26 CN CN2011800317444A patent/CN102985083A/zh active Pending
- 2011-04-26 MX MX2012012518A patent/MX337594B/es active IP Right Grant
- 2011-04-26 US US13/643,542 patent/US20130109759A1/en not_active Abandoned
-
2012
- 2012-11-13 ZA ZA2012/08535A patent/ZA201208535B/en unknown
-
2016
- 2016-03-10 JP JP2016046881A patent/JP6266674B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-17 US US15/407,831 patent/US20170354618A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013525443A5 (cg-RX-API-DMAC7.html) | ||
| JP2012525397A5 (cg-RX-API-DMAC7.html) | ||
| JP5902673B2 (ja) | 眼疾患の処置のためのキノンの製剤 | |
| EP2821405B1 (en) | Choline esters for treating presbyopia and cataract | |
| JP2011510965A (ja) | 高眼圧症の治療のためのジフルオロビフェニルアミド誘導体 | |
| RU2012109233A (ru) | Соединения как модуляторы тирозинкиназы | |
| EP2888239B1 (en) | Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes | |
| KR20150115812A (ko) | 플루오르화 인테그린 길항제 | |
| CN104203247A (zh) | 用于治疗眼部病症的4-孕甾烯-11ss-17-21-三醇-3，20-二酮衍生物 | |
| EP3099304B1 (en) | Chroman derivatives and their use in the treatment of glaucoma | |
| ITMI20080382A1 (it) | Composizioni farmaceutiche oculari | |
| JP7511564B2 (ja) | ミトコンドリア機能不全を治療する方法及び配合物 | |
| JP6405312B2 (ja) | 眼科用のキノン系一酸化窒素供与化合物 | |
| JP2022523332A (ja) | 近視を治療するための化合物、組成物及び方法 | |
| KR20150039126A (ko) | 눈꺼풀 치료 | |
| US20130158090A1 (en) | Metronidazole esters for treating rosacea | |
| EP3021870A1 (en) | Ophthalmic compositions containing a nitric oxide donor | |
| KR20190125370A (ko) | 인 함유 화합물 및 이의 제조와 약제 | |
| ES2391028T3 (es) | Compuestos tricíclicos citoprotectores | |
| JP5969872B2 (ja) | フラビンアデニンジヌクレオチドまたはその塩を有効成分として含有する角膜上皮細胞死の抑制剤 | |
| EP2588461B1 (en) | Metronidazole esters for treating rosacea | |
| US8802710B2 (en) | Metronidazole esters for treating rosacea | |
| AU2009205478A1 (en) | Therapeutic compounds | |
| JP6520019B2 (ja) | 新規スチルベン誘導体 | |
| EP3088388A1 (en) | Nitric oxide donating derivatives of prostaglandins |